Figure 2

hDT806 treatment enhances STING-IFN-I axis activities in HNSCC xenografts. (A) A schema shows the treatment procedure previously reported²⁹. When the JHU-029 HNSCC xenograft tumors reached an average size of ~ 80 mm³, intratumoral injection of vehicle or hDT806 was administered for 26 days. (B) The dissected tumors from NSG mice treated with vehicle or hDT806 after 26-day treatment were subject to immunohistochemistry (IHC) analysis for STING (a), IFNA1 (b), IFNB (c), CXCL10 (d), and MX1 (e). Inset scale bars = 30 µm. (C) Quantification of the IHC analysis shows hDT806 treatment increases the expression of STING (a), IFNA1 (b), IFNB (c), CXCL10 (d), and MX1 (e) in the JHU-029 xenograft tumors, compared to vehicle treatment. Data are presented as mean ± SEM (n = 4), with p values indicated.